-
1
-
-
84885184821
-
Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group
-
COI: 1:CAS:528:DC%2BC3sXht1ems7bF, PID: 23910494
-
Kim SJ, Hsu C, Song YQ, Tay K, Hong XN, Cao J, et al. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group. Eur J Cancer. 2013;49(16):3486–96.
-
(2013)
Eur J Cancer
, vol.49
, Issue.16
, pp. 3486-3496
-
-
Kim, S.J.1
Hsu, C.2
Song, Y.Q.3
Tay, K.4
Hong, X.N.5
Cao, J.6
-
2
-
-
84964260866
-
Prophylactic lamivudine to improve the outcome of HBsAg-positive lymphoma patients during chemotherapy: a systematic review and meta-analysis
-
PID: 25199680
-
Li H, Zhang HM, Chen LF, Chen YQ, Chen L, Ren H, et al. Prophylactic lamivudine to improve the outcome of HBsAg-positive lymphoma patients during chemotherapy: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2015;39(1):80–92.
-
(2015)
Clin Res Hepatol Gastroenterol.
, vol.39
, Issue.1
, pp. 80-92
-
-
Li, H.1
Zhang, H.M.2
Chen, L.F.3
Chen, Y.Q.4
Chen, L.5
Ren, H.6
-
3
-
-
43249109672
-
High prevalence of hepatitis B virus infection in patients with B-cell non-Hodgkin’s lymphoma in Korea
-
COI: 1:CAS:528:DC%2BD1cXmtlOhs70%3D, PID: 18428141
-
Park SC, Jeong SH, Kim J, Han CJ, Kim YC, Choi KS, et al. High prevalence of hepatitis B virus infection in patients with B-cell non-Hodgkin’s lymphoma in Korea. J Med Virol. 2008;80(6):960–6.
-
(2008)
J Med Virol
, vol.80
, Issue.6
, pp. 960-966
-
-
Park, S.C.1
Jeong, S.H.2
Kim, J.3
Han, C.J.4
Kim, Y.C.5
Choi, K.S.6
-
4
-
-
0033804328
-
Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors
-
COI: 1:CAS:528:DC%2BD3cXns1Ols7c%3D, PID: 11055239
-
Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000;62(3):299–307.
-
(2000)
J Med Virol
, vol.62
, Issue.3
, pp. 299-307
-
-
Yeo, W.1
Chan, P.K.2
Zhong, S.3
Ho, W.M.4
Steinberg, J.L.5
Tam, J.S.6
-
5
-
-
2342560548
-
Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy
-
COI: 1:CAS:528:DC%2BD2cXis1aitL0%3D, PID: 15054446
-
Yeo W, Zee B, Zhong S, Chan PK, Wong WL, Ho WM, et al. Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer. 2004;90(7):1306–11.
-
(2004)
Br J Cancer
, vol.90
, Issue.7
, pp. 1306-1311
-
-
Yeo, W.1
Zee, B.2
Zhong, S.3
Chan, P.K.4
Wong, W.L.5
Ho, W.M.6
-
6
-
-
84923090219
-
Hepatitis B reactivation during cancer chemotherapy: an international survey of the membership of the American Association for the Study of Liver Diseases
-
COI: 1:CAS:528:DC%2BC2MXhsVegsL3J, PID: 25220947
-
Hwang J, Barbo A, Perrillo R. Hepatitis B reactivation during cancer chemotherapy: an international survey of the membership of the American Association for the Study of Liver Diseases. J Viral Hepat. 2015;22(3):346–52.
-
(2015)
J Viral Hepat.
, vol.22
, Issue.3
, pp. 346-352
-
-
Hwang, J.1
Barbo, A.2
Perrillo, R.3
-
7
-
-
10744222282
-
Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy
-
COI: 1:CAS:528:DC%2BD2cXhtVOruw%3D%3D, PID: 14724827
-
Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003;125(6):1742–9.
-
(2003)
Gastroenterology
, vol.125
, Issue.6
, pp. 1742-1749
-
-
Lau, G.K.1
Yiu, H.H.2
Fong, D.Y.3
Cheng, H.C.4
Au, W.Y.5
Lai, L.S.6
-
8
-
-
84891429810
-
Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: a meta-analysis
-
COI: 1:CAS:528:DC%2BC3sXlt1Cntbw%3D, PID: 23562041
-
Dong HJ, Ni LN, Sheng GF, Song HL, Xu JZ, Ling Y. Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: a meta-analysis. J Clin Virol. 2013;57(3):209–14.
-
(2013)
J Clin Virol
, vol.57
, Issue.3
, pp. 209-214
-
-
Dong, H.J.1
Ni, L.N.2
Sheng, G.F.3
Song, H.L.4
Xu, J.Z.5
Ling, Y.6
-
9
-
-
33745753570
-
Kinetics and risk of de novo hepatitis B infection in HBsAg–negative patients undergoing cytotoxic chemotherapy
-
COI: 1:CAS:528:DC%2BD28XnvF2gsL0%3D, PID: 16831590
-
Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg–negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006;131(1):59–68.
-
(2006)
Gastroenterology
, vol.131
, Issue.1
, pp. 59-68
-
-
Hui, C.K.1
Cheung, W.W.2
Zhang, H.Y.3
Au, W.Y.4
Yueng, Y.H.5
Leung, A.Y.6
-
10
-
-
42249113025
-
Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy
-
PID: 18378948
-
Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008;148(7):519–28.
-
(2008)
Ann Intern Med
, vol.148
, Issue.7
, pp. 519-528
-
-
Loomba, R.1
Rowley, A.2
Wesley, R.3
Liang, T.J.4
Hoofnagle, J.H.5
Pucino, F.6
-
11
-
-
0032783736
-
Lamivudine. A review of its therapeutic potential in chronic hepatitis B
-
COI: 1:CAS:528:DyaK1MXltFOju7g%3D, PID: 10439933
-
Jarvis B, Faulds D. Lamivudine. A review of its therapeutic potential in chronic hepatitis B. Drugs. 1999;58(1):101–41.
-
(1999)
Drugs.
, vol.58
, Issue.1
, pp. 101-141
-
-
Jarvis, B.1
Faulds, D.2
-
12
-
-
0037221907
-
Histological outcome during long-term lamivudine therapy
-
COI: 1:CAS:528:DC%2BD3sXot1antQ%3D%3D, PID: 12512035
-
Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003;124(1):105–17.
-
(2003)
Gastroenterology
, vol.124
, Issue.1
, pp. 105-117
-
-
Dienstag, J.L.1
Goldin, R.D.2
Heathcote, E.J.3
Hann, H.W.4
Woessner, M.5
Stephenson, S.L.6
-
13
-
-
0032499913
-
A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group
-
COI: 1:CAS:528:DyaK1cXkvVSqtbY%3D, PID: 9654535
-
Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998;339(2):61–8.
-
(1998)
N Engl J Med
, vol.339
, Issue.2
, pp. 61-68
-
-
Lai, C.L.1
Chien, R.N.2
Leung, N.W.3
Chang, T.T.4
Guan, R.5
Tai, D.I.6
-
14
-
-
33845240185
-
Fatal postlymphoma chemotherapy hepatitis B reactivation secondary to the emergence of a YMDD mutant strain with lamivudine resistance in a noncirrhotic patient
-
PID: 16937392
-
Law JK, Ali JA, Harrigan PR, Sherlock CH, Savage KJ, Yoshida EM. Fatal postlymphoma chemotherapy hepatitis B reactivation secondary to the emergence of a YMDD mutant strain with lamivudine resistance in a noncirrhotic patient. Am J Hematol. 2006;81(12):969–72.
-
(2006)
Am J Hematol
, vol.81
, Issue.12
, pp. 969-972
-
-
Law, J.K.1
Ali, J.A.2
Harrigan, P.R.3
Sherlock, C.H.4
Savage, K.J.5
Yoshida, E.M.6
-
15
-
-
0036454880
-
Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B
-
PID: 12472959
-
Liaw YF. Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. J Gastroenterol Hepatol. 2002;17(s3):S333–7.
-
(2002)
J Gastroenterol Hepatol.
, vol.17
, Issue.s3
, pp. S333-S337
-
-
Liaw, Y.F.1
-
16
-
-
0030872946
-
Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus
-
COI: 1:CAS:528:DyaK2sXktlyrtbs%3D, PID: 9210663
-
Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, Colonno RJ. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother. 1997;41(7):1444–8.
-
(1997)
Antimicrob Agents Chemother.
, vol.41
, Issue.7
, pp. 1444-1448
-
-
Innaimo, S.F.1
Seifer, M.2
Bisacchi, G.S.3
Standring, D.N.4
Zahler, R.5
Colonno, R.J.6
-
17
-
-
35649020315
-
Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B
-
COI: 1:CAS:528:DC%2BD2sXhsVGqtr%2FI, PID: 17983800
-
Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology. 2007;133(5):1437–44.
-
(2007)
Gastroenterology
, vol.133
, Issue.5
, pp. 1437-1444
-
-
Gish, R.G.1
Lok, A.S.2
Chang, T.T.3
de Man, R.A.4
Gadano, A.5
Sollano, J.6
-
18
-
-
79951880002
-
Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy
-
PID: 21054683
-
Li HR, Huang JJ, Guo HQ, Zhang X, Xie Y, Zhu HL, et al. Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. J Viral Hepat. 2011;18(12):877–83.
-
(2011)
J Viral Hepat.
, vol.18
, Issue.12
, pp. 877-883
-
-
Li, H.R.1
Huang, J.J.2
Guo, H.Q.3
Zhang, X.4
Xie, Y.5
Zhu, H.L.6
-
19
-
-
84990312871
-
Clinical observation of preventing and treating HBV reactivation by lamivudine and entecavirin patients with non-Hodgkin lymphoma
-
COI: 1:CAS:528:DC%2BC3MXhsFyru7zK
-
Huang J, Chen XP, Chen XF, Chen WL. Clinical observation of preventing and treating HBV reactivation by lamivudine and entecavirin patients with non-Hodgkin lymphoma. J Prac Med. 2011;27(12):2225–7.
-
(2011)
J Prac Med.
, vol.27
, Issue.12
, pp. 2225-2227
-
-
Huang, J.1
Chen, X.P.2
Chen, X.F.3
Chen, W.L.4
-
20
-
-
0026088152
-
Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy
-
COI: 1:STN:280:DyaK3M%2FmtVSiuw%3D%3D
-
Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Rep Prospect Stud. Gastroenterol. 1991;100(1):182–8.
-
(1991)
Rep Prospect Stud. Gastroenterol.
, vol.100
, Issue.1
, pp. 182-188
-
-
Lok, A.S.1
Liang, R.H.2
Chiu, E.K.3
Wong, K.L.4
Chan, T.K.5
Todd, D.6
-
21
-
-
84919332882
-
Entecavir versus lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial
-
PID: 25514302
-
Huang H, Li X, Zhu J, Ye S, Zhang H, Wang W, et al. Entecavir versus lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. JAMA. 2014;312(23):2521–30.
-
(2014)
JAMA
, vol.312
, Issue.23
, pp. 2521-2530
-
-
Huang, H.1
Li, X.2
Zhu, J.3
Ye, S.4
Zhang, H.5
Wang, W.6
-
22
-
-
77957661914
-
Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
-
PID: 20652370
-
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.
-
(2010)
Eur J Epidemiol
, vol.25
, Issue.9
, pp. 603-605
-
-
Stang, A.1
-
23
-
-
84990311803
-
Comparison of lamivudine and entecavir in preventing hepatitis B reactivation in B-cell non-Hodgkin’S lymphoma patients during chemotherapy and the risk factors of hepatitis B occurrence
-
COI: 1:CAS:528:DC%2BC2MXhs1KgtrbE
-
Chen YM, Qian SX, Xie YP, Yang F. Comparison of lamivudine and entecavir in preventing hepatitis B reactivation in B-cell non-Hodgkin’S lymphoma patients during chemotherapy and the risk factors of hepatitis B occurrence. Zhejiang Med J. 2014;36(11):941–4.
-
(2014)
Zhejiang Med J.
, vol.36
, Issue.11
, pp. 941-944
-
-
Chen, Y.M.1
Qian, S.X.2
Xie, Y.P.3
Yang, F.4
-
24
-
-
67650724093
-
Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance
-
PID: 19454492
-
Ziakas PD, Karsaliakos P, Mylonakis E. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica. 2009;94(7):998–1005.
-
(2009)
Haematologica
, vol.94
, Issue.7
, pp. 998-1005
-
-
Ziakas, P.D.1
Karsaliakos, P.2
Mylonakis, E.3
-
25
-
-
84887572213
-
Prevelance of common YMDD motif mutations in long term treated chronic HBV infections in a Turkish population
-
PID: 24175847
-
Alagozlu H, Ozdemir O, Koksal B, Yilmaz A, Coskun M. Prevelance of common YMDD motif mutations in long term treated chronic HBV infections in a Turkish population. Asian Pac J Cancer Prev. 2013;14(9):5489–94.
-
(2013)
Asian Pac J Cancer Prev
, vol.14
, Issue.9
, pp. 5489-5494
-
-
Alagozlu, H.1
Ozdemir, O.2
Koksal, B.3
Yilmaz, A.4
Coskun, M.5
-
26
-
-
70349240414
-
Chronic hepatitis B: update 2009
-
PID: 19714720
-
Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661–2.
-
(2009)
Hepatology
, vol.50
, Issue.3
, pp. 661-662
-
-
Lok, A.S.1
McMahon, B.J.2
-
27
-
-
84990309113
-
Clinical comparison of preventive and therapeutic effects of lamivudine and entecavir on HBV reactivation among patients with non-Hodgkin lymphoma
-
COI: 1:CAS:528:DC%2BC2MXntValtbY%3D
-
Ni CB, Long B. Clinical comparison of preventive and therapeutic effects of lamivudine and entecavir on HBV reactivation among patients with non-Hodgkin lymphoma. J Clin Hepatol. 2014;30(4):363–6.
-
(2014)
J Clin Hepatol.
, vol.30
, Issue.4
, pp. 363-366
-
-
Ni, C.B.1
Long, B.2
-
28
-
-
84990314256
-
Comparison study of entecavir and lamivudine in treating hepatitis B reactivation in Non-Hodgkin lymphoma patients
-
Tan Y, Wu HF, Zou ML, Pan HC, Hu ZP, Wu JY. Comparison study of entecavir and lamivudine in treating hepatitis B reactivation in Non-Hodgkin lymphoma patients. Jiangxi Med J. 2014;49(9):854-67.
-
(2014)
Jiangxi Med J
, vol.49
, Issue.9
, pp. 854-867
-
-
Tan, Y.1
Wu, H.F.2
Zou, M.L.3
Pan, H.C.4
Hu, Z.P.5
Wu, J.Y.6
-
29
-
-
33644818518
-
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B
-
COI: 1:CAS:528:DC%2BD28XitFWms7Y%3D, PID: 16525137
-
Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354(10):1001–10.
-
(2006)
N Engl J Med
, vol.354
, Issue.10
, pp. 1001-1010
-
-
Chang, T.T.1
Gish, R.G.2
de Man, R.3
Gadano, A.4
Sollano, J.5
Chao, Y.C.6
-
30
-
-
33644822860
-
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B
-
COI: 1:CAS:528:DC%2BD28XitFWlsrY%3D, PID: 16525138
-
Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2006;354(10):1011–20.
-
(2006)
N. Engl. J. Med.
, vol.354
, Issue.10
, pp. 1011-1020
-
-
Lai, C.L.1
Shouval, D.2
Lok, A.S.3
Chang, T.T.4
Cheinquer, H.5
Goodman, Z.6
-
31
-
-
34447316464
-
Entecavir: a new nucleoside analogue for the treatment of chronic hepatitis B
-
COI: 1:CAS:528:DC%2BD2sXotV2msr8%3D, PID: 17460784
-
Rivkin A. Entecavir: a new nucleoside analogue for the treatment of chronic hepatitis B. Drugs Today. 2007;43(4):201–20.
-
(2007)
Drugs Today.
, vol.43
, Issue.4
, pp. 201-220
-
-
Rivkin, A.1
-
32
-
-
66149115173
-
Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy
-
COI: 1:CAS:528:DC%2BD1MXlslKmurw%3D, PID: 19280622
-
Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology. 2009;49(5):1503–14.
-
(2009)
Hepatology
, vol.49
, Issue.5
, pp. 1503-1514
-
-
Tenney, D.J.1
Rose, R.E.2
Baldick, C.J.3
Pokornowski, K.A.4
Eggers, B.J.5
Fang, J.6
-
33
-
-
33744531146
-
Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B
-
COI: 1:CAS:528:DC%2BD28XntVWitrw%3D, PID: 16762627
-
Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology. 2006;130(7):2039–49.
-
(2006)
Gastroenterology.
, vol.130
, Issue.7
, pp. 2039-2049
-
-
Sherman, M.1
Yurdaydin, C.2
Sollano, J.3
Silva, M.4
Liaw, Y.F.5
Cianciara, J.6
-
34
-
-
47149108478
-
Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks
-
COI: 1:CAS:528:DC%2BD1cXptFemtbc%3D, PID: 18537189
-
Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology. 2008;48(1):99–108.
-
(2008)
Hepatology
, vol.48
, Issue.1
, pp. 99-108
-
-
Sherman, M.1
Yurdaydin, C.2
Simsek, H.3
Silva, M.4
Liaw, Y.F.5
Rustgi, V.K.6
-
35
-
-
0028659004
-
Operating characteristics of a rank correlation test for publication bias
-
COI: 1:STN:280:DyaK2Mzgs1GrtQ%3D%3D, PID: 7786990
-
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101.
-
(1994)
Biometrics.
, vol.50
, Issue.4
, pp. 1088-1101
-
-
Begg, C.B.1
Mazumdar, M.2
|